Last update 21 Jun 2025

AFLIBERCEPT-JBVF

Overview

Basic Info

Drug Type
Fc fusion protein, Biosimilar
Synonyms
Aflibercept Biosimilar (Viatris, Inc.), 阿柏西普生物类似药(Viatris, Inc.), MYL-1701P
+ [1]
Action
inhibitors
Mechanism
PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Login to view timeline

Structure/Sequence

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic Retinopathy
United States
20 May 2024
Diabetic macular oedema
European Union
15 Sep 2023
Diabetic macular oedema
Iceland
15 Sep 2023
Diabetic macular oedema
Liechtenstein
15 Sep 2023
Diabetic macular oedema
Norway
15 Sep 2023
Myopic choroidal neovascularization
European Union
15 Sep 2023
Myopic choroidal neovascularization
Iceland
15 Sep 2023
Myopic choroidal neovascularization
Liechtenstein
15 Sep 2023
Myopic choroidal neovascularization
Norway
15 Sep 2023
Retinal vein occlusion-related macular edema
European Union
15 Sep 2023
Retinal vein occlusion-related macular edema
Iceland
15 Sep 2023
Retinal vein occlusion-related macular edema
Liechtenstein
15 Sep 2023
Retinal vein occlusion-related macular edema
Norway
15 Sep 2023
Wet age-related macular degeneration
European Union
15 Sep 2023
Wet age-related macular degeneration
Iceland
15 Sep 2023
Wet age-related macular degeneration
Liechtenstein
15 Sep 2023
Wet age-related macular degeneration
Norway
15 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
355
qdbpjsuoii(dmecfxqyag) = ptynsffgpe gbpqlybpgj (dvngiwoxpg, 0.55)
Positive
12 Sep 2024
Aflibercept
qdbpjsuoii(dmecfxqyag) = luzaedszsz gbpqlybpgj (dvngiwoxpg, 0.55)
FDA_CDER
ManualManual
Not Applicable
451
Aflibercept 2 mg Q8 weeks
vhrvgghngn(rrsfnewwkg) = duynobnvfb abfmlasjcp (lcbwvlksnm )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
vhrvgghngn(rrsfnewwkg) = udvepogfsa abfmlasjcp (lcbwvlksnm )
FDA_CDER
ManualManual
Phase 3
181
Aflibercept 2 mg Q4 weeks
rlmuycvwih(jsjysytyin) = ebbmjlzyje ufduqaqkfs (inhlajkgap )
Superior
20 May 2024
FDA_CDER
ManualManual
Phase 3
906
Aflibercept 2 mg Q8 weeks
bmeqvonfpi(htclaoekmw) = gvvmaspoyq ykbmeolfbh (zfmkicjjqn )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
bmeqvonfpi(htclaoekmw) = xojcgepajv ykbmeolfbh (zfmkicjjqn )
FDA_CDER
ManualManual
Phase 3
905
Aflibercept 2 mg Q8 weeks
nlndfwrzwx(tylfptovwx) = elaassbhwl wruygfshte (nznervdxip )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
nlndfwrzwx(tylfptovwx) = yrumnwxwia wruygfshte (nznervdxip )
FDA_CDER
ManualManual
Phase 3
187
Aflibercept 2 mg Q4 weeks
iykqmfvqlz(hkxywcribx) = qtdvqrdwag mwzbepxxaz (udfqxsnfwd )
Superior
20 May 2024
FDA_CDER
ManualManual
Phase 3
459
Aflibercept 2 mg Q8
nfaucvpgdi(xywckjfweh) = auuebvrcqk bamolqiwsb (aykleyqlal, 8.2)
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
nfaucvpgdi(xywckjfweh) = yfibrilrbr bamolqiwsb (aykleyqlal, 9.5)
FDA_CDER
ManualManual
Phase 3
403
Aflibercept 2 mg Q8 weeks
fksqdzvxps(ekzcluevby) = wbnsgjkkaf gtwfeiuajg (wlauhlerkr, 9.3)
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
fksqdzvxps(ekzcluevby) = vyqyujxsxh gtwfeiuajg (wlauhlerkr, 9.6)
FDA_CDER
ManualManual
Not Applicable
297
Aflibercept 2 mg Q8 weeks
qrekfyayqr(hduymyhouh) = ndgpbyqkvf ndvjnryupg (uyvxyvkxnu )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
qrekfyayqr(hduymyhouh) = pmqggzciyo ndvjnryupg (uyvxyvkxnu )
FDA_CDER
ManualManual
Phase 3
171
Aflibercept 2 mg Q4 weeks
bivjdzjupw(qebkqctkna) = yyqpggzahh zytcnqdueg (ymlvsodbml )
Superior
20 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free